Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK

ision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK Original Research (1620) Total Article Views Authors: Marty R, Roze S, Kurth H Published Date May 2012 Volume 2012:5 Pages 39 - 44 DOI: http://dx.doi.org/10.2147/MDER.S30913 Received: 16 February 2012 Accepted: 20 March 2012 Published: 01 May 2012 Rémi Marty1, Stéphane Roze1, Hannah Kurth2 1HEVA, Lyon, 2IPSEN, Boulogne-Billancourt, France Background: Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and neuroendocrine tumors. A simple decision-tree model aimed at comparing cost savings with ready-to-use Somatuline Autogel (lanreotide) and Sandostatin LAR (octreotide) for the UK, France, and Germany. The drivers of cost savings studied were the reduction of time to administer as well as a reduced baseline risk of clogging during product administration reported for Somatuline Autogel . Methods: The decision-tree model assumed two settings for SRL administration, ie, by either hospital-based or community-based nurses. In the case of clogging, the first dose was assumed to be lost and a second injection performed. Successful injection depended on the probability of clogging. Direct medical costs were included. A set of scenarios were run, varying the cost drivers, such as the baseline risk of clogging, SRL administration time, and percentage of patients injected during a hospital stay. Results: Costs per successful injection were less for Somatuline Autogel /Depot, ranging from Euros (EUR) 13-45, EUR 52-108, and EUR 127-151, respectively, for France, Germany, and the UK. The prices for both long-acting SRL were the same in France, and cost savings came to 100% from differences other than drug prices. For Germany and the UK, the proportion of savings due to less clogging and shorter administration time was estimated to be around 32% and 20%, respectively. Based on low and high country-specific patient cohort size estimations of individuals eligible for SRL treatment among the patient population with acromegaly and neuroendocrine tumors, annual savings were estimated to be up to EUR 2,000,000 for France, EUR 6,000,000 for Germany, and EUR 7,000,000 for the UK. Conclusion: This model suggests that increasing usage of the Somatuline device for injection of SRL might lead to substantial savings for health care providers across Europe.